Synthetic lethal targeting of TET2‐mutant haematopoietic stem and progenitor cells by XPO1 inhibitors

• Published in: British journal of haematology Vol. 201; no. 3; pp. 489 - 501
• Main Authors: Jing, Chang‐Bin, Prutsch, Nicole, He, Shuning, Zimmerman, Mark W., Landesman, Yosef, Look, A. Thomas
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.05.2023
• Subjects: Acute myeloid leukemia; Animals; Apoptosis; Ataxin; Cell death; clonal haematopoiesis; Dioxygenases - metabolism; DNA damage; DNA-Binding Proteins - genetics; eltanexor; Embryos; Exportin 1 Protein; Genetic transformation; Hematology; Hematopoietic Stem Cells - metabolism; Hemopoiesis; HSPC; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - pathology; Malignancy; Mice; Mutants; Progenitor cells; selinexor; TET2; XPO1; Zebrafish; TET2; XPO1; eltanexor; selinexor; clonal haematopoiesis; HSPC
• ISSN: 0007-1048; 1365-2141; 1365-2141
• DOI: 10.1111/bjh.18667

Summary TET2 inactivating mutations serve as initiating genetic lesions in the transformation of haematopoietic stem and progenitor cells (HSPCs). In this study, we analysed known drugs in zebrafish embryos for their ability to selectively kill tet2‐mutant HSPCs in vivo. We found that the exportin 1 (XPO1) inhibitors, selinexor and eltanexor, selectively kill tet2‐mutant HSPCs. In serial replating colony assays, these small molecules were selectively active in killing murine Tet2‐deficient Lineage‐, Sca1+, Kit+ (LSK) cells, and also TET2‐inactivated human acute myeloid leukaemia (AML) cells. Selective killing of TET2‐mutant HSPCs and human AML cells by these inhibitors was due to increased levels of apoptosis, without evidence of DNA damage based on increased γH2AX expression. The finding that TET2 loss renders HSPCs and AML cells selectively susceptible to cell death induced by XPO1 inhibitors provides preclinical evidence of the selective activity of these drugs, justifying further clinical studies of these small molecules for the treatment of TET2‐mutant haematopoietic malignancies, and to suppress clonal expansion in age‐related TET2‐mutant clonal haematopoiesis.